reports
- Oliver Metzger
Novartis to build new radioligand therapy site in Denton, Texas, deliv...
Novartis to build new radioligand therapy site in Denton, Texas, delivering more next‑generation treatments to patients Facility expected to be operational in 2028 in Dallas-Fort Worth area, expanding largest RLT manufacturing network in USSite to serve patients in Southern US and add network capacity as RLT expands into earlier treatment lines and additional tumor typesCompany broke ground on 4 new manufacturing and R&D facilities, initiated 3 facility expansions, and announced 2 additional sites in last 10 months, rapidly making progress on its commitment to expand its US operations East...
- Maxime Stranart
Sligro/FY25 results: Belgium remains a key issue/HOLD
We reiterate our HOLD rating on Sligro but increase our target price from €10.5 to €14.0, reflecting (1) an increase in our 2026 EBITDA forecast and (2) a lower net financial debt thanks to a strong FCF generation in 2H25. Despite these improvements, we remain cautious on the group's FCF generation going forward, as we understand that the strong performance in 2H25 was mainly driven by one-offs amounting to €30m at the working capital level, some of which will revert in FY26. Furthermore, we rem...
Press Release: Sanofi and Regeneron’s Dupixent approved in the US as t...
Press Release: Sanofi and Regeneron’s Dupixent approved in the US as the first and only medicine for allergic fungal rhinosinusitis Sanofi and Regeneron’s Dupixent approved in the US as the first and only medicine for allergic fungal rhinosinusitis Approval in adults and children aged 6 years and older supported by phase 3 study demonstrating Dupixent significantly reduced nasal signs and symptoms and systemic corticosteroid use or surgery compared to placeboAFRS is a chronic type 2 inflammatory disease of the sinuses characterized by an allergic hypersensitivity to fungi, often requiring ...
Communiqué de presse : Dupixent de Sanofi et Regeneron est approuvé au...
Communiqué de presse : Dupixent de Sanofi et Regeneron est approuvé aux États-Unis comme le premier et le seul médicament pour la rhinosinusite fongique allergique Dupixent de Sanofi et Regeneron est approuvé aux États-Unis comme le premier et le seul médicament pour la rhinosinusite fongique allergique Approbation chez les adultes et les enfants âgés de 6 ans et plus, appuyée par une étude de phase 3 démontrant que Dupixent a réduit de manière significative les signes et symptômes nasaux ainsi que le recours aux corticostéroïdes systémiques ou à la chirurgie par rapport au placeboL’AFRS e...
- Julian Dobrovolschi
- Julian Dobrovolschi
- Martial Descoutures
- Martial Descoutures
- ABGSC Healthcare Research
- Morten Larsen
Novo Nordisk A/S - share repurchase programme
Novo Nordisk A/S - share repurchase programme Bagsværd, Denmark, 23 February 2026 – On 4 February 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 15 billion to be executed during a 12-month period beginning 4 February 2026. Under the programme initiated 4 February 2026, Novo Nordisk will rep...
Novo Nordisk A/S: CagriSema demonstrated 23% weight loss in an open-la...
Novo Nordisk A/S: CagriSema demonstrated 23% weight loss in an open-label head-to-head REDEFINE 4 trial in people with obesity, the primary endpoint was not achieved CagriSema achieved 23% weight loss after 84 weeks of treatmentCagriSema 2.4/2.4 mg did not meet the primary endpoint of showing non-inferiority on weight loss compared to tirzepatide 15 mg at 84 weeks1Additional trials are exploring the full weight loss potential of CagriSema, including higher-dose combinations Bagsværd, Denmark, 23 February 2026 – Novo Nordisk today announced headline results from REDEFINE 4, an open-label ph...
Novo Nordisk A/S: Notice for the Annual General Meeting of Novo Nordis...
Novo Nordisk A/S: Notice for the Annual General Meeting of Novo Nordisk A/S Bagsværd, Denmark, 20 February 2026 – The Annual General Meeting will be held on: Thursday 26 March 2026 at 14:00 (CET) The Annual General Meeting will be held as a combined physical and virtual meeting. Accordingly, shareholders can choose between participating in person at Bella Center, Center Boulevard 5, entrance 6, 2300 Copenhagen S, Denmark, or virtually by PC or smartphone/tablet. We encourage shareholders to exercise their rights by submitting proxies or votes by correspondence in advance of the Annual Gen...
Press release: Filing of the 2025 U.S. Form 20-F and French “Document ...
Press release: Filing of the 2025 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report Filing of the 2025 U.S. Form 20-F and French “Document d’Enregistrement Universel” containing the Annual Financial Report Paris, February 17, 2026. Sanofi announces today the filing of its Form 20-F with the U.S. Securities and Exchange Commission (SEC) and its “Document d’Enregistrement Universel” containing its Annual Financial Report with the French market regulator Autorité des marchés financiers (AMF). These documents are available on the company’s ...
Communiqué de presse : Dépôt du Document d’Enregistrement Universel 20...
Communiqué de presse : Dépôt du Document d’Enregistrement Universel 2025, contenant le Rapport Financier Annuel, et du « Form 20-F » américain Dépôt du Document d’Enregistrement Universel 2025, contenant le Rapport Financier Annuel, et du « Form 20-F » américain Paris, le 17 février 2026. Sanofi annonce avoir déposé son Document d’Enregistrement Universel 2025 contenant le Rapport Financier Annuel auprès de l’Autorité des marchés financiers (AMF) en France et son « Form 20-F » auprès de la « Securities and Exchange Commission » (SEC) aux Etats-Unis. Le rapport du Conseil d’administration ...
Press Release: Sanofi and Teva’s duvakitug phase 2b maintenance data d...
Press Release: Sanofi and Teva’s duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn’s disease Sanofi and Teva’s duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn’s disease In the RELIEVE UCCD LTE phase 2b study, duvakitug showed robust, durable efficacy for an additional 44 weeks in UC and CD patients who had responded after 14 weeks of induction Duvakitug was well tolerated and safety was consistent with the induction studyFindings reinforce the potent...
Communiqué de presse : Les données de phase IIb de l’étude d’entretien...
Communiqué de presse : Les données de phase IIb de l’étude d’entretien sur le duvakitug de Sanofi et Teva ont démontré une efficacité durable cliniquement significative dans la colite ulcéreuse et la maladie de Crohn Les données de phase IIb de l’étude d’entretien sur le duvakitug de Sanofi et Teva ont démontré une efficacité durable cliniquement significative dans la colite ulcéreuse et la maladie de Crohn Dans l’étude de phase IIb RELIEVE UCCD LTE, le duvakitug a montré une efficacité robuste et durable pendant 44 semaines supplémentaires chez les patients atteints de CU et de MC qui ava...
Novo Nordisk A/S - share repurchase programme
Novo Nordisk A/S - share repurchase programme Bagsværd, Denmark, 16 February 2026 – On 4 February 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 15 billion to be executed during a 12-month period beginning 4 February 2026. Under the programme initiated 4 February 2026, Novo Nordisk will rep...
- Bruno Cavalier
- Markus Remis
EFGN EFG INTERNATIONAL AG
UHR SWATCH GROUP LTD. BEARER
RMS HERMES INTERNATIONAL SCA
EL ESSILORLUXOTTICA SA
BRBY BURBERRY GROUP PLC
KER KERING SA
SAF SAFRAN S.A.
CAP CAPGEMINI SE
01913 PRADA S.P.A.
MONC MONCLER SPA
STR STRABAG SE
BC BRUNELLO CUCINELLI S.P.A.
CFR COMPAGNIE FINANCIERE RICHEMONT SA
ABI ANHEUSER-BUSCH INBEV SA/NV
AZN ASTRAZENECA PLC
ADYEN ADYEN NV
MRNA MODERNA INC.
UMG UNIVERSAL MUSIC GROUP NV
ZGN ERMENEGILDO ZEGNA NV
QGEN QIAGEN N.V.
- Bruno Cavalier
- Markus Remis
EFGN EFG INTERNATIONAL AG
UHR SWATCH GROUP LTD. BEARER
RMS HERMES INTERNATIONAL SCA
EL ESSILORLUXOTTICA SA
BRBY BURBERRY GROUP PLC
KER KERING SA
SAF SAFRAN S.A.
CAP CAPGEMINI SE
01913 PRADA S.P.A.
MONC MONCLER SPA
STR STRABAG SE
BC BRUNELLO CUCINELLI S.P.A.
CFR COMPAGNIE FINANCIERE RICHEMONT SA
ABI ANHEUSER-BUSCH INBEV SA/NV
AZN ASTRAZENECA PLC
ADYEN ADYEN NV
MRNA MODERNA INC.
UMG UNIVERSAL MUSIC GROUP NV
ZGN ERMENEGILDO ZEGNA NV
QGEN QIAGEN N.V.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.